Clinical Trials Logo

Dry Eye Disease (DED) clinical trials

View clinical trials related to Dry Eye Disease (DED).

Filter by:
  • Completed  
  • Page 1

NCT ID: NCT05723770 Completed - Clinical trials for Dry Eye Disease (DED)

Effects of NOV03 on the Tear Film

Start date: August 14, 2023
Phase: Phase 4
Study type: Interventional

Determine the effect of a single instillation of NOV03 on the thickness and evaporation rate of the mucus-aqueous layer of the tear film

NCT ID: NCT04523142 Completed - Clinical trials for Dry Eye Disease (DED)

CyclASol for the Treatment of Signs and Symptoms of Dry Eye Disease in Subjects Who Completed CYS-004

Start date: January 4, 2021
Phase: Phase 3
Study type: Interventional

The objective of this trial is to evaluate safety and tolerability of CyclASol during long-term use in subjects with Dry Eye Disease.

NCT ID: NCT04393441 Completed - Clinical trials for Dry Eye Disease (DED)

Efficacy and Safety of a New Artificial Tear Formulation Compared With Systane Ultra Multidose in Participants With Dry Eye Disease

Start date: June 29, 2020
Phase: Phase 3
Study type: Interventional

The purpose of this study is to compare the efficacy and safety of a new artificial tear formulation (011516X) with Systane® Ultra Multidose for 90 days in participants with Dry Eye Disease (DED).

NCT ID: NCT04140227 Completed - Clinical trials for Dry Eye Disease (DED)

Long-Term Safety and Tolerability of NOV03 (Perfluorohexyloctane) in Subjects Who Completed Trial NVU-003 (Kalahari Study)

Start date: September 24, 2020
Phase: Phase 3
Study type: Interventional

The objectives of this trial are to evaluate the safety and tolerability of perfluorohexyloctane (NOV03) ophthalmic solution during long-term use in subjects with Dry Eye Disease (DED) associated with MGD (Meibomian Gland Dysfunction). Further objective is to evaluate the efficacy of perfluorohexyloctane (NOV03) solution during long-term use in subjects with DED associated with MGD.

NCT ID: NCT04139798 Completed - Clinical trials for Dry Eye Disease (DED)

Perfluorohexylcotane (NOV03) for the Treatment of Signs and Symptoms of Dry Eye Disease Associated With Meibomian Gland Dysfunction (Gobi Study)

Start date: July 20, 2020
Phase: Phase 3
Study type: Interventional

This trial will evaluate the efficacy, safety, and tolerability of NOV03 ophthalmic solution in comparison to a saline control for the treatment of the signs and symptoms of Dry Eye Disease (DED) associated with Meibomian Gland Dysfunction (MGD).

NCT ID: NCT04036292 Completed - Clinical trials for Dry Eye Disease (DED)

Evaluation of the Efficacy and Safety of OC-01 Nasal Spray on Signs and Symptoms of Dry Eye Disease

Start date: July 23, 2019
Phase: Phase 3
Study type: Interventional

The objective of this study is to evaluate the safety and effectiveness of OC-01 Nasal Spray as compared to placebo on signs and symptoms of dry eye disease.

NCT ID: NCT03333057 Completed - Clinical trials for Dry Eye Disease (DED)

Perfluorohexyloctane (NOV03) for the Treatment of Signs and Symptoms of Dry Eye Disease (DED)

Start date: January 3, 2018
Phase: Phase 2
Study type: Interventional

This study will evaluate the efficacy, safety and tolerability of perfluorohexyloctane (NOV03) at two different dosing regimens compared to saline solution in subjects with Dry Eye Disease (DED).

NCT ID: NCT01998802 Completed - Clinical trials for Dry Eye Disease (DED)

Phase 3 Study of EBI-005 in Dry Eye Disease

EBI-005
Start date: January 2014
Phase: Phase 3
Study type: Interventional

This is a phase III double-masked, randomized, controlled study evaluating the efficacy of EBI-005 as compared to vehicle given as a topical ophthalmic solution in each eye to subjects with moderate to severe DED three times daily for 12 weeks. Approximately 730 subjects at up to approximately 50 centers in the United States will be screened, enrolled into the study.